BrainCheck Raises Additional $13M Series A to Expand Digital Cognitive Assessment Platform
Memory is a fragile thing. One minute it is your sharpest asset. The next, it is a question mark hanging in the exam room. That is the space BrainCheck chose to walk into. Not the flashy side of health tech. The quiet, complicated side. Cognitive decline. Dementia. The conversations families avoid until they cannot. And now BrainCheck just secured $13M in additional Series A financing to push that mission further. Led by Next Coast Ventures, with S3 Ventures and UPMC Enterprises doubling down. When existing investors re-up, that is not politeness. That is conviction.
Credit where it is due. Chris Loughlin, CEO, is steering BrainCheck with a steady hand and a clear thesis. Yael Katz, PhD, co-founder and former CEO, laid the scientific and strategic foundation that made this moment possible. On the technology front, Bassel Samman, VP of Engineering, has been building the engine since 2015 and now drives the architecture forward. Enterprise traction does not happen by accident. It is designed.
BrainCheck is not just testing memory. It is building memory into the system. An FDA Class II cleared digital cognitive assessment. Longitudinal monitoring. Care planning that actually lives inside clinical workflows. More than 500 healthcare organizations across the U.S. are already using the platform. In a market where dementia is projected to impact 14M people in the U.S. and 152M globally, scale is not a vanity metric. It is oxygen.
The round itself tells a story. By November 2021, BrainCheck had raised more than $20M. Then $15M in March 2024. Now another $13M in February 2026. At least $48M in disclosed capital backing a bet that cognitive care belongs in primary care offices, neurology practices, geriatrics clinics, and value-based systems that actually carry risk. Capital follows clarity. And clarity comes from product-market fit.
Here is the business lesson hiding in plain sight. BrainCheck did not chase trends. It chased workflow. It embedded into health systems. It aligned with risk-bearing providers who need early detection and longitudinal insight, not another dashboard collecting dust. When you solve for reimbursement, regulatory clearance, and real clinical pain, investors do not need fireworks. They need proof.
Next Coast Ventures, S3 Ventures, and UPMC Enterprises are not tourists in digital health. They are builders and operators who understand that infrastructure wins over hype. BrainCheck is positioning itself as cognitive infrastructure, not a point solution. That nuance matters when hospitals decide what lives in their stack.
